The use of trastuzumab in New Zealand women with breast cancer.

about

Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes.

P2860

Q47804937-6879B6F7-4F52-4287-B5B6-BE8E539A157A

P2860

The use of trastuzumab in New Zealand women with breast cancer.

Item

http://www.wikidata.org/entity/Q48150633

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The use of trastuzumab in New Zealand women with breast cancer.

@en

The use of trastuzumab in New Zealand women with breast cancer.

@nl

type

Item

label

The use of trastuzumab in New Zealand women with breast cancer.

@en

The use of trastuzumab in New Zealand women with breast cancer.

@nl

prefLabel

The use of trastuzumab in New Zealand women with breast cancer.

@en

The use of trastuzumab in New Zealand women with breast cancer.

@nl

P1476

The use of trastuzumab in New Zealand women with breast cancer.

@en

P2093

Charis Brown

http://www.w3.org/2001/XMLSchema#string

Chunhuan Lao

http://www.w3.org/2001/XMLSchema#string

Ian Campbell

http://www.w3.org/2001/XMLSchema#string

Marion Kuper-Hommel

http://www.w3.org/2001/XMLSchema#string

Mark Elwood

http://www.w3.org/2001/XMLSchema#string

Sanjeewa Seneviratne

http://www.w3.org/2001/XMLSchema#string

Vernon Harvey

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Biology of breast cancer in young women.

Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.

Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study.

P304

e152-e160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJCO.12766

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ross Lawrenson

Melissa Edwards

P577

2017-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28856817

http://www.w3.org/2001/XMLSchema#string

P921

New Zealand

The use of trastuzumab in New Zealand women with breast cancer.

about

P2860

P2860

The use of trastuzumab in New Zealand women with breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921